RxDoctor Payments DataLook up a doctor →

Fawwaz Hamati, MD

Interventional Cardiology · Johnson City, TNNPI 1225023104

Payments from drug & device makers

$60,145in general payments, 2019–2025

Across 967 payments — averaging $62.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$21K
  • Abbott$13K
  • Boston Scientific$8K
  • Abiomed$4K
  • Cardiovascular Systems Inc.$3K
  • Novartis$2K
  • plus $10K from 36 others

What the payments were for

  • Travel & lodging$28,78156%
  • Food & beverage$22,12743%
  • Education$3981%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$60,145 in reported general payments places this provider in the 80th percentile of 207 interventional cardiology providers in Tennessee.

See all interventional cardiology providers in Tennessee

Medicare billing

Part B allowed, 2024
$313,922
Medicare patients
1,429
Services billed
3,896

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban385$393,426
EntrestoSacubitril/Valsartan273$316,870
XareltoRivaroxaban128$124,527
BrilintaTicagrelor108$83,655
JardianceEmpagliflozin34$30,920
MultaqDronedarone Hcl16$18,826
Metoprolol Succinate851$11,067
Repatha SyringeEvolocumab13$7,368
SotalolSotalol Hcl291$6,150
Prasugrel Hcl43$5,502
Diltiazem 24hr Er (Cd)Diltiazem Hcl138$4,209
Ranolazine ErRanolazine36$3,781
Flecainide Acetate72$3,021
ClopidogrelClopidogrel Bisulfate357$2,822
Dofetilide20$2,687

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$295$393,426385 claims
NovartisEntresto$1,947$316,870273 claims
Johnson & JohnsonXarelto$160$124,527128 claims
AstraZenecaBrilinta$1,192$83,655108 claims
Boehringer IngelheimJardiance$69$30,92034 claims
Sanofi-aventis U.S. LLCMultaq$57$18,82616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 207 interventional cardiology providers in Tennessee.

Other interventional cardiology in Johnson City

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →